Rhythm Pharmaceuticals Inc — 四半期キャッシュフロー (NASDAQ:RYTM) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 392.27 M386.69 M372.73 M506.87 M480.2 M 負債合計 227.72 M223.6 M239.15 M211.19 M210.17 M 純資産合計 21.73 M18.95 M-11.91 M148.82 M139.07 M 負債および純資産合計 392.27 M386.69 M372.73 M506.87 M480.2 M 有利子負債合計 109.81 M109.52 M109.79 M108.97 M108.18 M 純負債 -210.75 M-204.96 M-181.21 M-307.13 M-280.72 M

ニュース

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity - Slideshow (NASDAQ:RYTM) 2026-03-24

Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat

Needham、治験失敗を受けてRhythm Pharmaceuticalsの目標株価を引き下げ

Needham cuts Rhythm Pharmaceuticals stock price target on trial miss

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial - Slideshow (NASDAQ:RYTM) 2026-03-17

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript

Rhythm Pharma shares fall as obesity drug trial fails to meet main goal

リズム・ファーマシューティカルズ株が下落、肥満治療薬の治験が主要目標を達成できず